41O Nine weeks vs 1-year adjuvant trastuzumab: Long term outcomes of the ShortHER randomised trial
PierFranco Conte(University of Padua), Valentina Guarneri(Istituto Oncologico Veneto), Claudio Zamagni(Policlinico S.Orsola-Malpighi), Michela Donadio(Azienda Ospedaliero Universitaria San Giovanni Battista), Sara Balduzzi(Dutch Cancer Society), Silvio Danese(IRCCS Ospedale San Raffaele), Giancarlo Bisagni, Oriana Nanni(National Institutes of Health), Roberto Vicini, Antonino Musolino(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Antonio Frassoldati(Italian Oncology Group of Clinical Research), Luigi Cavanna(University of Pavia), Francesco Giotta(Istituto Tumori Bari), Maria Vittoria Dieci(Istituto Oncologico Veneto), Alba A. Brandes(Istituto delle Scienze Neurologiche di Bologna), Federico Piacentini(Azienda Unita' Sanitaria Locale Di Modena), Antonella Ferro(Ospedale Santa Chiara), Michele Aieta(Centro di Riferimento Oncologico della Basilicata), Vittorio Gebbia(La Maddalena), Ornella Garrone(Azienda Sanitaria Ospedaliera S.Croce e Carle Cuneo)
Cited by 5
Related Papers
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
|Gastroenterology|2021|2.6k
Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study
|Journal of Clinical Oncology|2000|2.3k
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
|The American Journal of Gastroenterology|2015|1.8k
Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.
|IRIS UNIMORE (University of Modena and Reggio Emilia)|2005|1.6k